Difference between revisions of "Hepatoblastoma"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%" to "{| class="wikitable sortable" style="width: 100%") |
||
Line 25: | Line 25: | ||
|} | |} | ||
===Regimen {{#subobject:9134b2|Variant=1}}=== | ===Regimen {{#subobject:9134b2|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 50: | Line 50: | ||
PLADO: '''<u>PLA</u>'''tinol (Cisplatin) & '''<u>DO</u>'''xorubicin | PLADO: '''<u>PLA</u>'''tinol (Cisplatin) & '''<u>DO</u>'''xorubicin | ||
===Regimen {{#subobject:c48515|Variant=1}}=== | ===Regimen {{#subobject:c48515|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 84: | Line 84: | ||
|} | |} | ||
===Regimen=== | ===Regimen=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
! style="width: 25%" |Study | ! style="width: 25%" |Study | ||
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
Revision as of 02:03, 26 September 2020
Section editor | |
---|---|
Wayne H. Liang, MD, MS UAB Birmingham, AL ![]() |
7 regimens on this page
7 variants on this page
|
All lines of therapy
Cisplatin monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Perilongo et al. 2009 (SIOPEL 3) | Phase III (E-de-esc) | Cisplatin & Doxorubicin | Non-inferior complete resection rate |
Chemotherapy
References
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed
Cisplatin & Doxorubicin
back to top |
PLADO: PLAtinol (Cisplatin) & DOxorubicin
Regimen
Study | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|
Ortega et al. 2000 | Phase III (E-switch-ic) | Cisplatin, 5-FU, Vincristine | More toxic | |
Perilongo et al. 2009 (SIOPEL 3) | Phase III (C) | Cisplatin | Non-inferior complete resection rate |
Chemotherapy
References
- Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD; Children's Cancer Group; Pediatric Oncology Group. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. link to original article PubMed
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed
Cisplatin, Fluorouracil, Vincristine
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Katzenstein et al. 2019 (AHEP0731) | Phase III (E-esc) | Observation | Seems to have superior EFS |
For stage 1 or 2 hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.
Preceding treatment
- Curative surgical resection
Chemotherapy
- Cisplatin as follows:
- Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
- 10 kg or more: 100 mg/m2 over 6 hours once on day 1
- Fluorouracil as follows:
- Less than 10 kg: 20 mg/kg IV once on day 2
- 10 kg or more: 600 mg/m2 IV once on day 2
- Vincristine as follows:
- Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
- 10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 2, 9, 16
21-day cycle for 1 cycle (to be given within 42 days of resection)
References
- AHEP0731: Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. link to original article PubMed